SOX9 and Hepatic fibrosis: Collectively these current and previous data highlight a potential clinical use for SOX9 and its downstream secreted targets as a measure to stratify patients with liver fibrosis alongside existing or emerging measures (e.g. cirrhosis risk score or liquid biomarkers)39–42.